T1	Participants 113 151	patients with metastatic breast cancer
T2	Participants 162 212	162 women (90 premenopausal and 72 postmenopausal)
T3	Participants 407 427	Twenty-three percent
T4	Participants 452 477	39% had partial remission
T5	Participants 479 497	28% had no change;
T6	Participants 502 528	3% had disease progression
T7	Participants 539 547	patients
T8	Participants 883 902	premenopausal women
T9	Participants 1329 1362	Patients with ER-positive disease
